243 related articles for article (PubMed ID: 10640214)
41. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
42. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
44. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
45. Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders.
Nafe R; Georgii A; Kaloutsi V; Fritsch RS; Choritz H
Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 61(2):111-6. PubMed ID: 1683718
[TBL] [Abstract][Full Text] [Related]
46. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
47. MPN blast phase: clinical challenge and assessing response.
Mesa RA; Tibes R
Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
[No Abstract] [Full Text] [Related]
48. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
49. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
50. Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: an immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies.
Thiele J; Braeckel C; Wagner S; Falini B; Dienemann D; Stein H; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1992; 421(1):33-9. PubMed ID: 1636247
[TBL] [Abstract][Full Text] [Related]
51. Chronic myeloproliferative disorders in bone marrow biopsies.
Georgii A; Vykoupil KF; Buhr T; Choritz H; Döhler U; Kaloutsi V; Werner M
Pathol Res Pract; 1990 Feb; 186(1):3-27. PubMed ID: 2179909
[TBL] [Abstract][Full Text] [Related]
52. [Successful low-dose etoposide therapy for a case of myelofibrosis with chronic myelogenous leukemia megakaryocytic predominance type].
Katayama T; Masuoka H; Yoshida M; Watanabe R; Nishiwaki K; Shimada T; Kaito K; Ochiai S; Kobayashi M; Sakai O
Rinsho Ketsueki; 1992 Apr; 33(4):488-93. PubMed ID: 1602613
[TBL] [Abstract][Full Text] [Related]
53. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
[TBL] [Abstract][Full Text] [Related]
54. [Histopathology of chronic myeloid leukemia in diagnostic biopsies of bone marrow].
Büsche G; Buhr T; Georgii A
Pathologe; 1995 Jan; 16(1):70-4. PubMed ID: 7886017
[TBL] [Abstract][Full Text] [Related]
55. Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?
Thiele J; Kvasnicka HM; Diehl V
Histol Histopathol; 2005 Apr; 20(2):633-44. PubMed ID: 15736066
[TBL] [Abstract][Full Text] [Related]
56. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
[TBL] [Abstract][Full Text] [Related]
57. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts.
Buhr T; Georgii A; Schuppan O; Amor A; Kaloutsi V
Ann Hematol; 1992 Jun; 64(6):286-91. PubMed ID: 1637884
[TBL] [Abstract][Full Text] [Related]
58. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
59. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
60. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
